3 Generic Drug Stocks to Watch Amid Improving Market Prospects
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
BofA Securities analyst Jason Gerberry maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average
Bank of America Securities Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Amphastar Pharmaceuticals(AMPH.US) Officer Sells US$147.17K in Common Stock
$Amphastar Pharmaceuticals(AMPH.US)$ Officer PETERS WILLIAM J sold 3,596 shares of common stock on Jun 27, 2024 at an average price of $40.9258 for a total value of $147.17K.Source: Announcement What
Form 144 | Amphastar Pharmaceuticals(AMPH.US) Officer Proposes to Sell 144.56K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Amphastar Pharmaceuticals(AMPH.US)$ Officer PETERS WILLIAM J intends to sell 3,596 shares of its common stock on Jun 27, with a total market value of approximately $14
Amphastar Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 73.47% Piper Sandler $71 → $71 Reiterates Overweight → Overweight 05/22/2024 — Needham Reitera
Investors in Amphastar Pharmaceuticals (NASDAQ:AMPH) Have Seen Impressive Returns of 101% Over the Past Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does wel
BetterInvesting Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) as its "Sto
Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)
Amphastar Pharmaceuticals(AMPH.US) Director Sells US$124.2K in Common Stock
$Amphastar Pharmaceuticals(AMPH.US)$ Director Petersen Floyd F. sold 3,000 shares of common stock on Jun 10, 2024 at an average price of $41.4 for a total value of $124.2K.Source: Announcement What is
Form 144 | Amphastar Pharmaceuticals(AMPH.US) Director Proposes to Sell 120K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Amphastar Pharmaceuticals(AMPH.US)$ Director Floyd Petersen intends to sell 3,000 shares of its common stock on Jun 10, with a total market value of approximately $120
With EPS Growth And More, Amphastar Pharmaceuticals (NASDAQ:AMPH) Makes An Interesting Case
Amphastar Pharmaceuticals(AMPH.US) Director Sells US$21,325.9 in Common Stock
$Amphastar Pharmaceuticals(AMPH.US)$ Director Petersen Floyd F. sold 500 shares of common stock on Jun 3, 2024 at an average price of $42.6518 for a total value of $21,325.9.Source: Announcement What
Express News | Amphastar Pharmaceuticals Authorized A $50M Increase To The Company's Share Buyback Program
Express News | Amphastar Pharmaceuticals Inc: Authorized a $50 Mln Increase to Company's Share Buyback Program
Amphastar Announces Additional $50 Million Increase to Its Share Buyback Program
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increas
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will par
Not Many Are Piling Into Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Just Yet
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) price-to-earnings (or "P/E") ratio of 13.2x might make it look like a buy right now compared to the market in the United States, where around half of th